Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03520842 | Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03679767 |
| A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) |
| completed |
| Phase 2 |
| 121 |
| Incyte CorporationINDUSTRY |
| 8 |
| Jul 21, 2023 |
| clinicaltrials |
| NCT02980991 | Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002) | completed | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT01833572 | Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | completed | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT00062010 | Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer | completed | Phase 2 | 37 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT00828009 | BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 70 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT00057837 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 140 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05116891 | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Cantargia ABINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT00064350 | Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer | completed | Phase 2 | 342 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00080938 | Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer | completed | Phase 2 | 26 | Eastern Cooperative Oncology GroupNETWORK | 0 | Jun 29, 2023 | clinicaltrials |
| NCT01824901 | Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00103207 | Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer | completed | Phase 2 | 72 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01104155 | Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 123 | Eisai Inc.INDUSTRY | 7 | Jun 22, 2023 | clinicaltrials |
| NCT01126736 | Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 98 | Eisai Inc.INDUSTRY | 5 | Jun 22, 2023 | clinicaltrials |
| NCT00006004 | Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 15, 2023 | clinicaltrials |
| NCT00041314 | Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 15, 2023 | clinicaltrials |
| NCT03345810 | Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)(DURATION) | completed | Phase 2 | 200 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03743129 | Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）(ALTER-L029) | completed | Phase 2 | 90 | Anhui Shi, MDOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03373760 | Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer | completed | Phase 2 | 67 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 9, 2023 | clinicaltrials |
| NCT02666105 | Exemestane in Post-Menopausal Women With NSCLC | completed | Phase 2 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT01004731 | Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer | completed | Phase 1 / Phase 2 | 7 | University of Alabama at BirminghamOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT02766335 | Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | completed | Phase 2 / Phase 3 | 116 | SWOG Cancer Research NetworkNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT04507217 | Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC | completed | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT03102242 | Atezolizumab Immunotherapy in Patients With Advanced NSCLC | completed | Phase 2 | 64 | Alliance Foundation Trials, LLC.OTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT02045446 | Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial | completed | Phase 2 | 29 | University of Texas Southwestern Medical CenterOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03304093 | Immunotherapy by Nivolumab for HIV+ Patients(CHIVA2) | completed | Phase 2 | 30 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT00301808 | Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 29 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT03455829 | G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | G1 Therapeutics, Inc.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT02659059 | Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer(CheckMate 568) | completed | Phase 2 | 324 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 5, 2023 | clinicaltrials |
| NCT03406468 | Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer | completed | Phase 2 | 36 | Maastricht Radiation OncologyOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05792995 | Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes | completed | Phase 2 | 80 | Xin-Hua XuOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT02872701 | OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules | completed | Phase 2 | 100 | On Target Laboratories, LLCINDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT00385606 | Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC | completed | Phase 2 / Phase 3 | 400 | National Cancer Institute, NaplesOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT01296113 | Chemotherapy for Lung Cancer in HIV-positive Patients(CHIVA) | completed | Phase 2 | 61 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03825510 | Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect(I-SABR) | completed | Phase 2 | 3 | Crozer-Keystone Health SystemOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03904563 | Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma | completed | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT02151604 | Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy | completed | Phase 2 | 22 | Oxford University Hospitals NHS TrustOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 117 | AmMax Bio, Inc.INDUSTRY | 6 | Jan 20, 2023 | clinicaltrials |
| NCT03693547 | Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） | completed | Phase 2 | 26 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 10, 2023 | clinicaltrials |
| NCT00312728 | A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) | completed | Phase 2 | 115 | Genentech, Inc.INDUSTRY | 0 | Jan 6, 2023 | clinicaltrials |
| NCT02591615 | Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC | completed | Phase 2 | 91 | Alliance Foundation Trials, LLC.OTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT04201756 | Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma | completed | Phase 2 | 47 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 19 | Gan and Lee Pharmaceuticals, USAINDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT03853187 | Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer(Donan) | completed | Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03090737 | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer(CheckMate 907) | completed | Phase 2 | 129 | Bristol-Myers SquibbINDUSTRY | 5 | Dec 5, 2022 | clinicaltrials |
| NCT03360929 | Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 | completed | Phase 1 / Phase 2 | 15 | LYZZ Alpha Holding LtdINDUSTRY | 1 | Nov 25, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 1, 2023source: clinicaltrials